
Keywords: کم خونی همولیتی اتوایمیون; AIHA; autoimmune hemolytic anemia; B2M; β2-microglobulin; BR; bendamustine and rituximab; BTK; Bruton tyrosine kinase; CLL; chronic lymphocytic leukemia; CR; complete remission; FCR; fludarabine; cyclophosphamide; and rituximab; FISH; fluorescence in sit